From the Amyvid web site: http://www.amyvid.com

Quote:

---

Amyvid is approved for use in adults with thinking or memory problems who are being assessed for Alzheimer's Disease (AD) or other causes of these symptoms. Amyvid is used by doctors in combination with other tests.

Amyvid is used with a positron emission tomography (PET) scanner to show whether high levels of plaques, which are a buildup of a protein called beta-amyloid, are in the brain.

A negative Amyvid scan means that there are few to no plaques in the brain and makes it unlikely that AD is the cause of symptoms at the time of the scan.

A positive Amyvid scan means that the amount of plaque in the brain is similar to the amount seen in people with AD. This amount of plaque may also be seen in people with other conditions of the brain that cause thinking or memory problems, as well as in older people with normal thinking and memory.

A positive Amyvid scan does not diagnose AD or other thinking or memory disorders. Amyvid is not approved to predict the development of dementia or other brain conditions in the future or for monitoring the effectiveness of treatments.

---

We'll find out soon enough whether LymPro data indicates we'll overtake this "gold standard" diagnostic test. From the data published so far, and from what's published in the LymPro white paper, I believe it will. So do a lot of other well-informed folks.

Disclaimer : I am not a physician, nor do I have a medical degree. I don't believe this is a requirement to be a successful investor in biotech companies. But if I did have a medical degree, I assure you I'd be licensed to practice medicine, and I'd be able to discuss a competing product using the correct product name.